Skip to content

A Randomized Double-blind Controlled Clinical Trial of Kefir to Improve Vascular Stiffness in Patients with Mild to Moderate Hypertension

The effect of Kefir on the improvement of vascular stiffness in patients with mild to moderate hypertension

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073490
Enrollment
Unknown
Registered
2023-07-12
Start date
2023-07-15
Completion date
Unknown
Last updated
2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertension

Interventions

the group of Kefir :Standard antihypertensive therapy + Kefir 2g po bid
Goat milk group:Standard antihypertensive treatment + oat milk powder 2g po bid

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. age 18-75 years old, no limit on gender; 2. meet the diagnostic criteria for mild to moderate hypertension in the Chinese Health Management Code for Hypertension (2019); 3. 3 oral antihypertensive medications are taken, do not adjust antihypertensive medications within 2 weeks before enrollment and had stable blood pressure. 4. could communicate well with medical staff, voluntarily participated and sign the informed consent form. Those who meet all of the above are included in this study.

Exclusion criteria

Exclusion criteria: 1. patients with clearly proven secondary hypertension; 2. heart failure occurring within 3 months; 3. ACS occurring within 3 months or expected PCI or CABG; 4. ischemic/hemorrhagic stroke occurring within 3 months; 5. diabetes mellitus not well controlled (fasting glucose >11.1 mmol/L); 6. malignancy or other disease affecting 5-year survival; 7. abnormal liver function 8. renal impairment with blood creatinine >133mmol/L; 9. gastric ulcer 10. patients with severe chronic obstructive pulmonary disease; bronchial asthma not well controlled; 11. severe arrhythmias affecting hemodynamics; 12. active rheumatic immune diseases; 13. various acute and chronic infectious diseases and acute metabolic disorders 14. pregnant or lactating women or those with pregnancy plans; 15. those with stressful conditions such as surgery or severe trauma; 16. those with severe allergies, known or likely to be allergic to Corexit or its constituents; 17. those with psychiatric disorders, drug or other substance abuse. If any of the above is met, it is excluded.

Design outcomes

Primary

MeasureTime frame
pulse-wave velocity;

Secondary

MeasureTime frame
Clinic blood pressure;ceramide;glycosylated hemoglobin;blood fat;

Countries

China

Contacts

Public ContactZhao Shaohua

Qilu Hospital of Shandong University

zhaosh1001@163.com+86 185 6008 6556

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026